PRGO - Perrigo Corp Total Debt to Capital

Public company logo of Perrigo Company plc (PRGO)

Perrigo Company plc (PRGO) relies on the production of private-label products for pharmacies, which provides the company with defensive qualities during economic downturns. However, fierce competition in the generics segment and regulatory inspections create certain challenges. The leverage ratio is 1.36. The price action of the over-the-counter manufacturer, which attracts industry experts and develops an internal talent pool, is presented in the chart below.

PRGO: Perrigo Total Debt to Capital 07/04/2022 - 10/29/2026

Analytical breakdowns for Perrigo Company plc

- price and consensus price forecast:
Price Chart Perrigo|PRGO - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization Perrigo|PRGO - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Perrigo|PRGO - Book Capitalization|Market Value to Book Value Ratio perrigo.com|PRGO - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Perrigo Company plc|PRGO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Perrigo Company plc|PRGO - Company Aggregate Debts|Debt to Book Value Perrigo|PRGO - Company Long-Term Loans and Borrowings|Company Short-Term Debt Perrigo
Basic company analysis:Perrigo
Core merchandise of Perrigo Corp

Investors assess the margin of safety for Perrigo Company plc (PRGO) via the total liabilities-to-equity ratio to determine the business's degree of dependence on external financing. Stable demand for over-the-counter drugs allows Perrigo Company plc (PRGO) to optimize this leverage metric on GURU.Markets, transforming borrowed resources into a tool for scaling production while maintaining its status as a reliable asset.

Competitor analysis for Perrigo Company plc

Debt to Equity Haleon|Kenvue Inc - Aggregate Debt to Equity|Total Debt to Capital VRNA|MENS (Jyong Bio) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LGND (Ligand Pharmaceuticals)|Total Debt to Capital amneal.com AMRX|ALVO - Debt to Equity|All Debt to Shareholders' Equity Ratio LQDA (Liquidia Corp)|Galapagos Genomics (GLPG) - Debt to Equity|Total Debt to Equity Ratio ANI Pharmaceuticals Corp|MNKD (MannKind Corporation) - Total Debt to Capital|Total Debt to Capital amphastar.com|Total Debt to Equity Ratio PCRX (Pacira BioSciences, Inc.)|SPRY (ARS Pharmaceuticals Inc) - All Debt to Shareholders' Equity Ratio|Debt to Equity Theravance TBPH|Aquestive Corp (AQST) - Debt to Capital|SCPH: Total Debt to Equity Ratio|Tectonic Therapeutic, Inc. - Aggregate Debt to Capital|TNXP: Total Debt to Capital|China SXT Pharmaceuticals, Inc. - All Debt to Shareholders' Equity Ratio|EPRX (Eupraxia Pharmaceuticals, Inc.) - Total Debt to Capital|Debt to Capital BioHarvest Sciences Inc BHST|Debt to Equity eXoZymes Inc (EXOZ)|ORMP (oramed.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Entera Bio ENTX|HYFT (MindWalk Holdings, Inc.) - Aggregate Debt to Equity|ABVC BioPharma Inc - Total Debt to Capital|Debt to Capital Cumberland Corp|Quantum BioPharma Ltd (QNTM) - Debt to Equity|fibrogen.com - All Debt to Shareholders' Equity Ratio|Debt to Equity Telomir Pharmaceuticals, Inc.|RANI: All Debt to Shareholders' Equity Ratio|Total Debt to Capital SNYR|Total Debt to Capital Coefficient rallybio.com|Total Debt to Capital LEXX (Lexaria Bioscience Corp.)|Debt to Capital Ratio pulmatrix.com|PTHL - Debt to Equity|Debt to Capital Aptorum Group Limited|LYRA (Lyra Therapeutics, Inc) - Total Debt to Equity Ratio|Impact BioMedical, Inc. - All Debt to Shareholders' Equity Ratio|TNFA (TNF Pharmaceuticals Inc.) - Total Debt to Capital|Total Debt to Equity Ratio cbdMD Corp (YCBD)|Debt to Equity PainReform (PRFX)|CYTO - Debt to Capital|Debt to Equity Lipella LIPO|OPTN - Total Debt to Equity Ratio|PIRS - Debt to Equity|Aggregate Debt to Equity PROC|PTPI: Total Debt to Capital|Qilian International Holding Group (QLI) - Total Debt to Capital|Debt to Equity ACELYRIN, Inc.|Debt to Equity Ratio TFFP (TFF Pharmaceuticals, Inc)